» Articles » PMID: 37375736

Innate Vascular Failure by Application of Neuroleptics, Amphetamine, and Domperidone Rapidly Induced Severe Occlusion/Occlusion-like Syndromes in Rats and Stable Gastric Pentadecapeptide BPC 157 As Therapy

Abstract

Even before behavioral disturbances, neuroleptics, amphetamine, and domperidone application rapidly emerged severe occlusion/occlusion-like syndrome, shared innate vascular and multiorgan failure in rats, comparable to occlusion/occlusion-like syndrome described with vessel(s) occlusion or similar noxious procedures application. As therapy, i.e., activation of the collateral pathways, "bypassing key" (activated azygos vein pathway, direct blood flow delivery), the stable gastric pentadecapeptide BPC 157 is a novel solution. Recently, BPC 157 therapy particularly counteracted neuroleptic- or L-NAME-induced catalepsy, lithium intoxication, and schizophrenia positive and negative symptoms (amphetamine/methamphetamine/apomorphine/ketamine). In rats with complete calvariectomy, medication (BPC 157 10 µg/kg, 10 ng/kg ip or ig) was given 5 min after distinctive dopamine agents (mg/kg ip) (haloperidol (5), fluphenazine (5), clozapine (10), risperidone (5), olanzapine (10), quetiapine (10), or aripiprazole (10), domperidone (25), amphetamine (10), and combined amphetamine and haloperidol) and assessed at 15 min thereafter. All neuroleptic-, domperidone-, and amphetamine-induced comparable vascular and multiorgan failure severe syndrome was alleviated with BPC 157 therapy as before major vessel(s) occlusion or other similar noxious procedures. Specifically, all severe lesions in the brain (i.e., immediate swelling, hemorrhage), heart (i.e., congestion, arrhythmias), and lung (i.e., congestion, hemorrhage), as well as congestion in the liver, kidney, and gastrointestinal (stomach) tract, were resolved. Intracranial (superior sagittal sinus), portal, and caval hypertension and aortal hypotension were attenuated or eliminated. BPC 157 therapy almost annihilated arterial and venous thrombosis, peripherally and centrally. Thus, rapidly acting Virchow triad circumstances that occur as dopamine central/peripheral antagonists and agonist essential class-points, fully reversed by BPC 157 therapy, might be overwhelming for both neuroleptics and amphetamine.

Citing Articles

Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review.

Bajramagic S, Sever M, Rasic F, Staresinic M, Skrtic A, Beketic Oreskovic L Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204186 PMC: 11357423. DOI: 10.3390/ph17081081.


New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection.

Sikiric P, Sever M, Krezic I, Vranes H, Kalogjera L, Smoday I Inflammopharmacology. 2024; 32(5):3119-3161.

PMID: 38980576 DOI: 10.1007/s10787-024-01499-8.


The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity.

Sikiric P, Boban Blagaic A, Strbe S, Beketic Oreskovic L, Oreskovic I, Sikiric S Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675421 PMC: 11053547. DOI: 10.3390/ph17040461.


From Selye's and Szabo's Cysteamine-Duodenal Ulcer in Rats to Dopamine in the Stomach: Therapy Significance and Possibilities.

Sikiric P, Boban Blagaic A, Krezic I, Zizek H, Kalogjera L, Smoday I Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139825 PMC: 10748240. DOI: 10.3390/ph16121699.


Stable Gastric Pentadecapeptide BPC 157 Therapy: Effect on Reperfusion Following Maintained Intra-Abdominal Hypertension (Grade III and IV) in Rats.

Tepes M, Krezic I, Vranes H, Smoday I, Kalogjera L, Zizek H Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004420 PMC: 10675657. DOI: 10.3390/ph16111554.


References
1.
Wood J . The first nobel prize for integrated systems physiology: Ivan Petrovich Pavlov, 1904. Physiology (Bethesda). 2004; 19:326-30. DOI: 10.1152/physiol.00034.2004. View

2.
Gojkovic S, Krezic I, Vranes H, Zizek H, Drmic D, Pavlov K . BPC 157 Therapy and the Permanent Occlusion of the Superior Sagittal Sinus in Rat: Vascular Recruitment. Biomedicines. 2021; 9(7). PMC: 8301421. DOI: 10.3390/biomedicines9070744. View

3.
Vukojevic J, Siroglavic M, Kasnik K, Kralj T, Stancic D, Kokot A . Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157. Vascul Pharmacol. 2018; 106:54-66. DOI: 10.1016/j.vph.2018.02.010. View

4.
Schimpf R, Veltmann C, Papavassiliu T, Rudic B, Goksu T, Kuschyk J . Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide. Heart Rhythm. 2012; 9(5):776-81. PMC: 3482382. DOI: 10.1016/j.hrthm.2012.01.006. View

5.
Lally J, MacCabe J . Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015; 114(1):169-79. DOI: 10.1093/bmb/ldv017. View